Chronic Rhinosinusitis Trial, Recruiting NCT07399665 Sponsor: AstraZeneca Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Chronic Rhinosinusitis Trial, Recruiting

NCT07399665
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older at the time of signing the consent form
  • You have been diagnosed with chronic sinusitis with nasal polyps for at least 1 year before starting tezepelumab treatment
  • Your medical records from at least 1 year before starting tezepelumab are available, including details about any steroid use, nasal polyp surgery, or reasons why those treatments were not suitable for you
  • You have been prescribed and have already started treatment with tezepelumab, and no more than 4 weeks have passed since you started it
  • Your nasal polyps are severe enough that surgery would normally be considered, based on a specific polyp size score measured at enrollment (confirm with trial site)
  • You have a significant level of nasal blockage, as measured by a standard symptom questionnaire score at enrollment (confirm with trial site)
  • Your overall sinus symptom score on a standard questionnaire is at a certain level at enrollment or within the 12 weeks before joining (confirm with trial site)
  • You are currently receiving care from a specialist doctor, such as an ear, nose and throat (ENT) doctor, at the trial site
  • You are willing and able to sign and date a consent form
  • You are able to read, understand, and fill in the questionnaires required by the study

Who may not be able to join:

  • You have a medical reason why you should not take tezepelumab, based on official guidance or your doctor's opinion
  • You are currently taking another biological medicine for your nasal polyps or asthma (though stable allergy immunotherapy is allowed, and switching from a previous biological medicine to tezepelumab may be permitted if at least 60 days have passed since your last dose of the previous medicine)
  • You are currently taking part in another observational study that could affect this trial's results, or you have taken part in an interventional clinical trial in the last 3 months
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
25 December 2025
Est. completion
31 March 2028

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

1. Change in endoscopic status of CRSwNP based on NPS; 2. Change in a nasal congestion status based on Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22); 3. Change in endoscopic status of CRSwNP based on NPS; 4. Change in a nasal congestion status based on Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov